B. Riley maintained an $85 price target on Viking Therapeutics (VKTX), highlighting early preclinical findings for its amylin candidate VK3019. The reported monkey study showed 12.0% weight loss over 19 days, while the company is also exploring longer-acting molecules that could support less-frequent dosing. 🔹 Key Highlights Analyst Price Target: B. Riley's reported target is $85. VK3019 Results: Reported 12.0% weight loss over 19 days in monkey dosing. Comparison: The update described the result as nearly three times the weight loss achieved by VK2735 in its own comparison and greater than the cited tirzepatide result over eight weeks. Longer-Acting Candidates: Two backup molecules reportedly have twice the duration of action. Combination Potential: The findings raise the possibility of a once-monthly combination injection. VK2735 Data: Cholesterol and triglyceride improvements reportedly persisted after moving from weekly to monthly maintenance dosing. Upcoming Catalyst: First human VK3019 data are expected in Q4 2026. Valuation: B. Riley's commentary cited an enterprise value of approximately $2.4 billion. 💡 Why It Matters VK3019 could provide Viking with another potential growth opportunity beyond VK2735, particularly if longer-acting amylin treatments can support convenient maintenance dosing. However, the 12.0% weight-loss result comes from animal testing and should not be treated as evidence of equivalent human efficacy. First-in-human data will be a key milestone. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified